| Irit Arbel |
Irit Arbel founded Brainstorm Cell Therapeutics, Inc. in 2000, where she is working as Vice Chairman from 2020, BRH Medical Ltd. in 2009, where she worked as Chairman from 2009 to 2011, and Neurocords Corp. in 2018, where she is working as Chief Executive Officer & Director from 2018. Dr. Arbel also currently works at American Society of Hematology, as Member and American Neurological Association, as Member. Dr. Arbel also formerly worked at Pluri, Inc., as President & Chief Executive Officer from 2002 to 2004, ATC Systems, Inc., as Chief Executive Officer from 2009 to 2010, Real Aesthetics Ltd., as Chairman from 2009 to 2011, RFB Investment House, as Director-Mergers & Acquisitions, Isracann Biosciences, Inc., as Independent Director from 2019 to 2022, Online Disruptive Technologies, Inc., as Executive Vice President-Research & Development from 2012 to 2018, Global Energy, Inc., as Investor Relations Contact from 2011 to 2012, Merck Sharp & Dohme Corp., as Sales Manager, and Savicell Diagnostic Ltd., as Executive Vice President-Research & Development from 2012 to 2018. Dr. Arbel received her undergraduate degree from Technion-Israel Institute of Technology. |
| Stacy R. Lindborg |
Stacy R. Lindborg is currently an Independent Director at Imunon, Inc., a Director at Brainstorm Cell Therapeutics, Inc., a Director at Slone Career Strategies, Inc., and a Director at Massachusetts Down Syndrome Congress. Previously, she worked at Eli Lilly & Co. as the Head of Research & Development Strategy from 1996 to 2012, and at Biogen, Inc. as the Vice President of Analytics & Data Science from 2018 to 2020. Dr. Lindborg obtained her undergraduate, graduate, and doctorate degrees from Baylor University in 1992, 1993, and 1996 respectively. |
| Sidney A. Spector |
Presently, Sidney A. Spector is Senior VP-Global Strategy & Medical Affairs at Brainstorm Cell Therapeutics, Inc. Dr. Spector is also Associate Professor at the University of Arizona College of Medicine and Chief Medical Officer at Proxenia Venture Partners LLC.
In his past career Dr. Spector occupied the position of Vice President-US Medical Affairs at Novartis Gene Therapies, Inc. and Vice President at AveXis EU Ltd.
Dr. Spector received a doctorate from the University of California, Los Angeles and a doctorate from Sackler School of Medicine. |
| Kim Thacker |
Presently, Kim Thacker is Senior VP-Medical Affairs & Clinical Innovation at Brainstorm Cell Therapeutics, Inc. He is also President for American Tap Dance Foundation.
In the past he occupied the position of Vice President-Medical Affairs for UroGen Pharma Ltd.
Dr. Thacker received a doctorate from State University of New York at Downstate Medical Center. |
| Bob Dagher |
Bob Dagher's career history includes current and former positions as well as his education. Currently, he is the Chief Medical Officer & Executive Vice President at Brainstorm Cell Therapeutics, Inc. Prior to this, he held the position of Senior Medical Director at Labcorp Drug Development, Inc. from 2018 to 2019. From 2019 to 2021, he served as the Chief Medical Officer-WCG MedAvante-ProPhase at Cadent Therapeutics, Inc. He also held the position of Chief Medical Officer at MedAvante-ProPhase, Inc. Additionally, from 2021 to 2023, he was the Chief Medical Officer at Enveric Biosciences, Inc. Dr. Dagher completed his undergraduate degree at Université de Bordeaux and Faculté De Médecine Necker Enfants Malades Université. |
| Netta Blondheim-Shraga |
Netta Blondheim-Shraga is currently the Vice President-Research & Development at Brainstorm Cell Therapeutics, Inc. She has a graduate degree from Tel-Aviv University, an undergraduate degree from The Hebrew University of Jerusalem, and a doctorate from Bar-Ilan University and the Faculty of Medicine. |
| Antal Pearl-Lendner |
Antal Pearl-Lendner is currently the Chief Legal Counsel & Vice President at Brainstorm Cell Therapeutics, Inc. She graduated from Tel-Aviv University with a graduate degree and earned an MBA from MIT Sloan School of Management. |
| Jacob Aharon Frenkel |
Jacob Aharon Frenkel is currently the Chairman at Brainstorm Cell Therapeutics, Inc., Plus500 Ltd., and The Group of Thirty. He is also a Director at the Peter G. Peterson Institute for International Economics, the National Bureau of Economic Research, Inc., the Council for the United States & Italy, the Aspen Institute Italia, the Japan Society, the Institute for National Security Studies, and Vivion Investments SARL. Additionally, he is a Member of The Trilateral Commission. Previously, Dr. Frenkel served as the Chief Executive Officer & Governor of the Bank of Israel from 1991 to 2000. He was also the Vice Chairman of American International Group, Inc. in 2009, the Vice Chairman-Governors Board of the European Bank for Reconstruction & Development from 1999 to 2000, and the Chairman of JPMorgan Chase & Co. from 2009 to 2020. He held the position of Chairman-Governors Board at the Inter-American Development Bank from 1995 to 1996 and at Merrill Lynch International, Inc. from 2000 to 2004. Furthermore, he was the Chairman-Governors Board of Tel-Aviv University from 2013 to 2021. He served as an Independent Director at Loews Corp. from 2009 to 2019 and at Boston Properties, Inc. from 2010 to 2019. He was also a Director at Boston Properties LP. Dr. Frenkel's education includes a graduate and doctorate degree from The University of Chicago and an undergraduate degree from The Hebrew University of Jerusalem. |
| Uri Yablonka |
Uri Yablonka is currently the Secretary, Director, Chief Business Officer & EVP at Brainstorm Cell Therapeutics, Inc. Prior to this, he was the Vice President-Business Development at ACC International Holdings Ltd. from 2011 to 2014. He also served as the General Manager & Owner of Mr. Yablonka Ltd. Additionally, he worked as a Senior Partner at Pm Pr Media Consulting Ltd. from 2008 to 2011. |
| Yael Gothelf |
Yael Gothelf is currently the Vice President of Scientific & Regulatory Affairs at Brainstorm Cell Therapeutics, Inc. since 2007. Prior to this, Yael worked as a Scientific Manager for Research & Process Development at Interpharm Laboratories Ltd. Yael holds a doctorate degree from Tel-Aviv University. |
| Alla Patlis |
Alla Patlis is currently the Chief Financial Officer & Controller at Brainstorm Cell Therapeutics, Inc. She previously worked at Deloitte Touche Tohmatsu Ltd. as a Member. She completed her undergraduate degree and MBA at Tel-Aviv University. |
| Chaim Lebovits |
Chaim Lebovits is currently the President & Chief Executive Officer at Brainstorm Cell Therapeutics, Inc. and a Director at Dominion Minerals Corp. He is also the President of ACC Holdings International. Previously, he served as a Non-Executive Director at Calima Energy Ltd. from 2010 to 2012. |
| June Sherie Almenoff |
June Sherie Almenoff is Chief Medical Officer at RedHill Biopharma Ltd. She is also on the board of Tenax Therapeutics, Inc., Brainstorm Cell Therapeutics, Inc. and Avalo Therapeutics, Inc.
In the past she occupied the position of Chief Operating & Medical Officer at 9 Meters Biopharma, Inc. and Director at RDD Pharma Ltd. (a subsidiary of 9 Meters Biopharma, Inc.), President, CEO, Director & Chief Marketing Officer at Furiex Pharmaceuticals, Inc., Vice President-Clinical Safety Organization at GlaxoSmithKline LLC and Member of Infectious Diseases Society of America.
June Sherie Almenoff received an undergraduate degree from Smith College and a doctorate from Icahn School of Medicine at Mount Sinai. |
| Menghisteab Bairu |
Menghisteab Bairu is the founder of Proxenia Venture Partners LLC, which was founded in 2016. He is currently the President & CEO of Bio Usawa, Inc. and an Independent Director at Brainstorm Cell Therapeutics, Inc. He is also a Director at Serenus Biotherapeutics, Inc. and a Board Member at Himalayan Cataract Project. In the past, he served as Chairman & Chief Executive Officer at Bairex Medical, Executive Chairman at Treos Bio Ltd., Medical Director at Fremont Health Corp., Chief Medical Officer & Head-Development at Elan Corp. Plc, and Executive Vice President at Prothena Therapeutics Ltd. He also served as a Director at Alzheon, Inc. and A-CUBE, Inc. and as a Board Member at NewBridge Pharmaceuticals FZ LLC. He holds a doctorate degree from the University of Milan. |
| Anthony J. Polverino |
Anthony J. Polverino is an Independent Director at Brainstorm Cell Therapeutics, Inc. He was previously an Executive Director at Amgen, Inc., Chief Scientific Officer at Kite Pharma, Inc., and Chief Scientific Officer & EVP-Early Development at Zymeworks BC, Inc. Polverino received his undergraduate degree from the University of Adelaide and his doctorate from Flinders University. |
| Nir Naor |
Nir Naor is an Independent Director at Brainstorm Cell Therapeutics, Inc. and the Chief Financial Officer at Axogen, Inc. He previously worked as an Auditor at KPMG Corporate Finance LLC from 2001 to 2005. From 2012 to 2017, he served as the Chief Financial Officer-United States at UCB SA. In 2021, he briefly held the position of Chief Financial Officer at Arbor Pharmaceuticals, Inc. From 2017 to 2021, he was the Chief Financial Officer-US Americas at Molnlycke Health Care US LLC. Mr. Naor completed his undergraduate and graduate degrees at Tel-Aviv University and also holds a graduate degree from the University of Hamburg. He further obtained an MBA from the International Institute for Management Development. |
